drugset / Trial / NCT07542548
D-Cycloserine for Serine Palmitoyltransferase Inhibition
Phase 4
Completed
1 enrolled
Massachusetts General Hospital
National Institute of General Medical Sciences (NIGMS) · collabUniformed Services University of the Health Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia
Timeline
- Start
- 2024-07-10
- Primary completion
- 2026-03-17
- Completion
- 2026-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cycloserine | Small molecule | 15 mg/kg | Oral |
| Subject | Cycloserine | Small molecule | 20 mg/kg | Oral |
| Background | Pyridoxine | Unknown | 20 mg | Oral |